Adverse effect · 5-Amino-1MQ

How common is safety in humans with 5-Amino-1MQ?

D
Grade D — no human evidenceNone · effect size: not measurable · adverse
Short answerNo human evidence. As of 3 September 2026, only none exist for 5-Amino-1MQ for safety in humans. No human dosing study exists; there is no safety dataset. NNMT sits at a hub of NAD+ and methylation metabolism, so systemic inhibition has plausible but unstudied off-target effects.

What the studies show

No human dosing study exists; there is no safety dataset. NNMT sits at a hub of NAD+ and methylation metabolism, so systemic inhibition has plausible but unstudied off-target effects.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

5-Amino-1MQ is a small molecule — not a peptide — that blocks an enzyme called NNMT, which is elevated in the fat tissue of obese people. In mice, inhibiting NNMT reduces fat mass and improves metabolic markers, which is the basis of its sale as a weight-loss and metabolic 'peptide'. It has never been tested in a controlled human trial and is not approved anywhere.

5-Amino-1MQ is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is 5-Amino-1MQ proven to cause safety in humans?
No. There is no human evidence for it (None); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
No human dosing study exists; there is no safety dataset. NNMT sits at a hub of NAD+ and methylation metabolism, so systemic inhibition has plausible but unstudied off-target effects.
Is 5-Amino-1MQ approved for this?
No. 5-Amino-1MQ is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for 5-Amino-1MQ

Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →